
Oncotelic Therapeutics Featured in Editorial Highlighting Biotech M&A Focus on Late-Stage Assets
Oncotelic Therapeutics' alignment with biotech M&A trends prioritizing clinically validated, late-stage oncology and CNS assets underscores the company's strategic positioning as it advances its therapeutic platform.
Read full story





















